Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study

Rupert Bartsch, Catharina Wenzel, Dagmar Hussian, Ursula Pluschnig, Ursula Sevelda, Wolfgang Koestler, Gabriela Altorjai, Gottfried J Locker, Robert Mader, Christoph C Zielinski, Guenther G Steger, Rupert Bartsch, Catharina Wenzel, Dagmar Hussian, Ursula Pluschnig, Ursula Sevelda, Wolfgang Koestler, Gabriela Altorjai, Gottfried J Locker, Robert Mader, Christoph C Zielinski, Guenther G Steger

Abstract

Background: Combining trastuzumab and chemotherapy is standard in her2/neu overexpressing advanced breast cancer. It is not established however, whether trastuzumab treatment should continue after the failure of one earlier combination. In this trial, we report our experience with continued treatment beyond disease progression.

Methods: Fifty-four patients, median age 46 years, range 25-73 years, were included. We analysed for time to tumour progression (TTP) for first, second and beyond second line treatment, response rates and overall survival.

Results: Median time of observation was 24 months, range 7-51. Response rates for first line treatment were 7.4% complete remission (CR), 35.2% partial remissions (PR), 42.6% stable disease > 6 months (SD) and 14.8% of patients experienced disease progression despite treatment (PD). Corresponding numbers for second line were 3.7% CR, 22.2% PR, 42.6% SD and 31.5% PD; numbers for treatment beyond second line (60 therapies, 33 pts 3rd line, 18 pts 4th line, 6 pts 5th line, 2 pts 6th line and 1 patient 7th line) were 1.7% CR, 28.3% PR, 28.3% SD and 41.6% PD respectively. Median TTP was 6 months (m) in the first line setting, and also 6 m for second line and beyond second line. An asymptomatic drop of left ventricular ejection fraction below 50% was observed in one patient. No case of symptomatic congestive heart failure was observed.

Conclusion: The data presented clearly strengthen evidence that patients do profit from continued trastuzumab treatment. The fact that TTP did not decrease significantly from first line to beyond second line treatment is especially noteworthy. Still, randomized trials are warranted.

Figures

Figure 1
Figure 1
Time to progression (months) for 1st, 2nd, 3rd, and 4th line trastuzumab based combination therapy.

References

    1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol. 2005;2:68–75.
    1. Hill C, Doyon F. The frequency of cancer in France in the year 2000, and trends since 1950. Bull Cancer. 2005;92:7–11.
    1. Mollick JA, Carlson RW. Rational surveillance programs for early stage breast cancer patients after primary treatment. Breast Dis. 2004;21:47–54.
    1. Cianfranco M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9:606–16. doi: 10.1634/theoncologist.9-6-606.
    1. Subramaniam DS, Isaacs C. Utilizing prognostic and predicative markers in breast cancer. Curr Treat Options Oncol. 2005;6:147–59.
    1. Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol. 2002;29:38–43.
    1. Thomssen C. Trials of new combinations of Herceptin in metastatic breast cancer. Anticancer Drugs. 2001;12:19–25.
    1. Vogel CL, Franco SX. Clinical experience with trastuzumab (herceptin) Breast J. 2003;9:452–62. doi: 10.1046/j.1524-4741.2003.09602.x.
    1. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Trastuzumab and Vinorelbine as first-line therapy for Her2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003;21:2889–95. doi: 10.1200/JCO.2003.02.018.
    1. Winer EP, Burstein HJ. New combinations with herceptin in metastatic breast cancer. Oncology. 2001;61:50–7. doi: 10.1159/000055402.
    1. Yarden Y, Baselga J, Miles D. Molecular approach to breast cancer treatment. Semin Oncol. 2004;31:6–13. doi: 10.1053/j.seminoncol.2004.07.016.
    1. Esteva FJ. Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. Oncologist. 2004;9:4–9. doi: 10.1634/theoncologist.9-suppl_3-4.
    1. Bianco AR. Targeting c-erbB2 and other receptors of the c-erbB family: rationale and clinical applications. J Chemother. 2004;16:52–4.
    1. Jahanzeb M, Mortimer JE, Yunus F, Irwin DH, Speyer J, Koletsky AJ, Klein P, Sabir T, Kronish L. Phase II trial of weekly Vinorelbine and Trastuzumab as first-line therapy in patients with Her2(+) metastatic breast cancer. Oncologist. 2002;7:410–7. doi: 10.1634/theoncologist.7-5-410.
    1. Montemurro F, Valabrega G, Aglietta M. Trastuzumab-based combination therapy for breast-cancer. Expert Opin Pharmacother. 2004;5:81–96. doi: 10.1517/14656566.5.1.81.
    1. Jahanzeb M. Trastuzumab-Based Combinations in Metastatic Breast Cancer: How to Make a Choice. Clinical Breast Cancer. 2003;1:28–38.
    1. Suzuki Y, Tokuda Y, Saito Y, Ohta M, Tajima T. Combination of trastuzumab and vinorelbine in metastatic breast cancer. Jpn J Clin Oncol. 2003;33:514–7. doi: 10.1093/jjco/hyg101.
    1. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP. Clinical activity of trastuzumab and vinorelbine in women with Her2-overexpressing breast cancer. J Clin Oncol. 2004;15:2722–30.
    1. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tibuana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM. Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered as First-Line Treatment: Results of a Randomized Phase II Trial by the M77001 Study group. J Clin Oncol. 2005;23:4265–74. doi: 10.1200/JCO.2005.04.173.
    1. Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S, Dias R, Ghahramani P. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol. 2003;21:3965–71. doi: 10.1200/JCO.2003.12.109.
    1. Kaplan EL, Meier P. Non parametric estimation for incomplete observations. J Am Stat Ass. 1958;53:457–481.
    1. Fountzilas G, Razis E, Tsavdaridis D, Karina M, Labropoulos S, Christodoulou C, Mavroudis D, Gogas H, Georgoulias V, Skarlos D. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic cooperative oncology group. Clin Breast Cancer. 2003;4:120–5.
    1. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004;22:1063–70. doi: 10.1200/JCO.2004.06.557.
    1. Gelmon KA, Mackey J, Verma S, Gertler SZ, Bangemann N, Kilmo P, Schneeweiss A, Bremer K, Soulieres D, Tonkin K, Bell R, Heinrich B, Grenier D, Dias R. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer. 2004;5:52–8.
    1. Osoba D. Health-related quality of life as a treatment endpoint in metastatic breast cancer. Can J Oncol. 1995;5:47–53.
    1. Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med. 1992;35:1505–9. doi: 10.1016/0277-9536(92)90053-S.
    1. Eiermann W. trastuzumab combined with chemotherapy for the treatment of HER"-positive metastatic breast cancer: pivotal trial data. Ann Oncol. 2001;12:57–62. doi: 10.1023/A:1011172125897.
    1. Ritter CA, Bianco R, Dugger T, Forbes J, Qu S, Rinehart C, King W, Arteaga CL. Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model. Int J Pharmacol Ther. 2004;42:642–3.
    1. Vidal L, Attard G, Kaye S, De Bono J. Reversing resistance to targeted therapy. J Chemother. 2004;16:7–12.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa